世界の非黒色腫皮膚がん治療市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV04008)
◆英語タイトル:Global Non-Melanoma Skin Cancer Treatment Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV04008
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2023年版があります。お問い合わせください。)
◆ページ数:132
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥538,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥807,300見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,076,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは非黒色腫皮膚がん治療の世界市場について調査・分析した資料です。種類別(化学療法、放射線療法、光線力学療法)の市場規模、用途別(病院、診療所、外来外科センター、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別非黒色腫皮膚がん治療の競争状況、市場シェア
・世界の非黒色腫皮膚がん治療市場:種類別市場規模 2015年-2020年(化学療法、放射線療法、光線力学療法)
・世界の非黒色腫皮膚がん治療市場:種類別市場規模予測 2021年-2026年(化学療法、放射線療法、光線力学療法)
・世界の非黒色腫皮膚がん治療市場:用途別市場規模 2015年-2020年(病院、診療所、外来外科センター、その他)
・世界の非黒色腫皮膚がん治療市場:用途別市場規模予測 2021年-2026年(病院、診療所、外来外科センター、その他)
・北米の非黒色腫皮膚がん治療市場分析:米国、カナダ
・ヨーロッパの非黒色腫皮膚がん治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの非黒色腫皮膚がん治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の非黒色腫皮膚がん治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの非黒色腫皮膚がん治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Boehringer Ingelheim、Bristol-Myers Squibb、Eli Lilly、Roche、Merck、Novartis、Mylan、Sun Pharmaceutical、Almirall、Elekta、Varian Medical Systems、Sensus Healthcare、iCAD、Accuray、Ion Beam Applications
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts.
Radiation therapy has a market share approaching 88% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon.

Market Analysis and Insights: Global Non-Melanoma Skin Cancer Treatment Market
The global Non-Melanoma Skin Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Non-Melanoma Skin Cancer Treatment Scope and Market Size
Non-Melanoma Skin Cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Melanoma Skin Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Roche
Merck
Novartis
Mylan
Sun Pharmaceutical
Almirall
Elekta
Varian Medical Systems
Sensus Healthcare
iCAD
Accuray
Ion Beam Applications

Market segment by Type, the product can be split into
Chemotherapy
Radiation Therapy
Photodynamic Therapy
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Melanoma Skin Cancer Treatment Revenue
1.4 Market by Type
1.4.1 Global Non-Melanoma Skin Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Radiation Therapy
1.4.4 Photodynamic Therapy
1.5 Market by Application
1.5.1 Global Non-Melanoma Skin Cancer Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Non-Melanoma Skin Cancer Treatment Market Perspective (2015-2026)
2.2 Global Non-Melanoma Skin Cancer Treatment Growth Trends by Regions
2.2.1 Non-Melanoma Skin Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Melanoma Skin Cancer Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Melanoma Skin Cancer Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Melanoma Skin Cancer Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Non-Melanoma Skin Cancer Treatment Players by Market Size
3.1.1 Global Top Non-Melanoma Skin Cancer Treatment Players by Revenue (2015-2020)
3.1.2 Global Non-Melanoma Skin Cancer Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Melanoma Skin Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Melanoma Skin Cancer Treatment Market Concentration Ratio
3.2.1 Global Non-Melanoma Skin Cancer Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Melanoma Skin Cancer Treatment Revenue in 2019
3.3 Non-Melanoma Skin Cancer Treatment Key Players Head office and Area Served
3.4 Key Players Non-Melanoma Skin Cancer Treatment Product Solution and Service
3.5 Date of Enter into Non-Melanoma Skin Cancer Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Non-Melanoma Skin Cancer Treatment Historic Market Size by Type (2015-2020)
4.2 Global Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)
5.2 Global Non-Melanoma Skin Cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
6.2 Non-Melanoma Skin Cancer Treatment Key Players in North America (2019-2020)
6.3 North America Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
6.4 North America Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
7.2 Non-Melanoma Skin Cancer Treatment Key Players in Europe (2019-2020)
7.3 Europe Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
7.4 Europe Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

8 China
8.1 China Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
8.2 Non-Melanoma Skin Cancer Treatment Key Players in China (2019-2020)
8.3 China Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
8.4 China Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
9.2 Non-Melanoma Skin Cancer Treatment Key Players in Japan (2019-2020)
9.3 Japan Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
9.4 Japan Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
10.2 Non-Melanoma Skin Cancer Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

11 India
11.1 India Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
11.2 Non-Melanoma Skin Cancer Treatment Key Players in India (2019-2020)
11.3 India Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
11.4 India Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Non-Melanoma Skin Cancer Treatment Market Size (2015-2020)
12.2 Non-Melanoma Skin Cancer Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Melanoma Skin Cancer Treatment Market Size by Type (2015-2020)
12.4 Central & South America Non-Melanoma Skin Cancer Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Details
13.1.2 Boehringer Ingelheim Business Overview
13.1.3 Boehringer Ingelheim Non-Melanoma Skin Cancer Treatment Introduction
13.1.4 Boehringer Ingelheim Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020))
13.1.5 Boehringer Ingelheim Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Non-Melanoma Skin Cancer Treatment Introduction
13.2.4 Bristol-Myers Squibb Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Non-Melanoma Skin Cancer Treatment Introduction
13.3.4 Eli Lilly Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Non-Melanoma Skin Cancer Treatment Introduction
13.4.4 Roche Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Non-Melanoma Skin Cancer Treatment Introduction
13.5.4 Merck Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Non-Melanoma Skin Cancer Treatment Introduction
13.6.4 Novartis Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Mylan
13.7.1 Mylan Company Details
13.7.2 Mylan Business Overview
13.7.3 Mylan Non-Melanoma Skin Cancer Treatment Introduction
13.7.4 Mylan Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.7.5 Mylan Recent Development
13.8 Sun Pharmaceutical
13.8.1 Sun Pharmaceutical Company Details
13.8.2 Sun Pharmaceutical Business Overview
13.8.3 Sun Pharmaceutical Non-Melanoma Skin Cancer Treatment Introduction
13.8.4 Sun Pharmaceutical Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.8.5 Sun Pharmaceutical Recent Development
13.9 Almirall
13.9.1 Almirall Company Details
13.9.2 Almirall Business Overview
13.9.3 Almirall Non-Melanoma Skin Cancer Treatment Introduction
13.9.4 Almirall Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.9.5 Almirall Recent Development
13.10 Elekta
13.10.1 Elekta Company Details
13.10.2 Elekta Business Overview
13.10.3 Elekta Non-Melanoma Skin Cancer Treatment Introduction
13.10.4 Elekta Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
13.10.5 Elekta Recent Development
13.11 Varian Medical Systems
10.11.1 Varian Medical Systems Company Details
10.11.2 Varian Medical Systems Business Overview
10.11.3 Varian Medical Systems Non-Melanoma Skin Cancer Treatment Introduction
10.11.4 Varian Medical Systems Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.11.5 Varian Medical Systems Recent Development
13.12 Sensus Healthcare
10.12.1 Sensus Healthcare Company Details
10.12.2 Sensus Healthcare Business Overview
10.12.3 Sensus Healthcare Non-Melanoma Skin Cancer Treatment Introduction
10.12.4 Sensus Healthcare Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.12.5 Sensus Healthcare Recent Development
13.13 iCAD
10.13.1 iCAD Company Details
10.13.2 iCAD Business Overview
10.13.3 iCAD Non-Melanoma Skin Cancer Treatment Introduction
10.13.4 iCAD Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.13.5 iCAD Recent Development
13.14 Accuray
10.14.1 Accuray Company Details
10.14.2 Accuray Business Overview
10.14.3 Accuray Non-Melanoma Skin Cancer Treatment Introduction
10.14.4 Accuray Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.14.5 Accuray Recent Development
13.15 Ion Beam Applications
10.15.1 Ion Beam Applications Company Details
10.15.2 Ion Beam Applications Business Overview
10.15.3 Ion Beam Applications Non-Melanoma Skin Cancer Treatment Introduction
10.15.4 Ion Beam Applications Revenue in Non-Melanoma Skin Cancer Treatment Business (2015-2020)
10.15.5 Ion Beam Applications Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Boehringer Ingelheim、Bristol-Myers Squibb、Eli Lilly、Roche、Merck、Novartis、Mylan、Sun Pharmaceutical、Almirall、Elekta、Varian Medical Systems、Sensus Healthcare、iCAD、Accuray、Ion Beam Applications

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の非黒色腫皮膚がん治療市場2026:インサイト・予測(Global Non-Melanoma Skin Cancer Treatment Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。